Mark your calendars: On September 26 and 27, 2025, the Ophthalmology Times and Optometry Times EyeCon 2025 conference will convene at the Margaritaville Hollywood Beach Resort in Hollywood, Florida.

K8 was found to reduce geographic atrophy lesion area growth by more than 50% in its first human clinical trial of the drug.

In addition to the proxy statement, STAAR has reached out to all stockholders to ask for their vote to adopt the merger agreement.

The studies compared the Unity Vitreoretinal Cataract System (VCS) to the Constellation Vision System and the Centurion Vision System with Active Sentry.

Travoprost is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Belite Bio completes its phase 3 trial for tinlarebant, a potential first treatment for Stargardt disease, with results expected in late 2025.

A panelist discusses how a 50-year-old male patient with stabilized keratoconus achieved excellent visual outcomes with an IC-8 small aperture IOL by targeting slight myopia to optimize the defocus curve, followed by adjunctive PRK to address central corneal astigmatism that was causing ghosting despite good uncorrected acuity, emphasizing the critical importance of controlling irregularities in the central 3-mm zone and ensuring nighttime pupil size remains under 5 mm for optimal results.

A panelist discusses how a 40-year-old female patient seeking freedom from glasses experienced a complicated course with a light adjustable lens that resulted in poor visual quality and 22 clinic visits, but was successfully salvaged through lens exchange to an IC-8 small aperture IOL after demonstrating the benefits with a simple pinhole occluder test.

A panelist discusses how the IC-8 Apthera small aperture IOL functions as a pinhole-based optical system that blocks distorted peripheral light while allowing focused light from both distance and near targets to travel through the same pathway, creating an extended depth of focus that ophthalmologists have long awaited in the United States.

We ask leading experts in the field what eye disease they would cure and why.

Viridian plans to submit a Biologics License Application (BLA) for VRDN-003 by year-end of 2026.

Kwangdong, a top 5 pharmaceutical and healthcare company in Korea, is actively involved in research and development innovation, including “transformational late-stage, high-impact technologies.”